Aurealis Therapeutics presented advancements in multi-target bacterial gene therapies at the 14th International Symposium on Lactic Acid Bacteria

Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, is making remarkable advances in the field with its 4-in-1 technology platform. Director of Genetic Engineering & Manufacturing, Igor Mierau, showcased the company’s research and results at the 14th International Symposium on Lactic Acid Bacteria, held […]

Aurealis Therapeutics shines in Nordic Life Science News with in-depth interview on gene therapy innovations

Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer, is excited to share its recent feature in the well-known life science journal, Nordic Life Science News. The article titled “From Theory to Therapy: Gene Therapy” has shared remarkable insights from an interview with Laurent Décory, COO […]

Aurealis Therapeutics accelerates oncology program: First abstract published at ASCO as the team prepares for Annual Meeting in Chicago

Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for unmet medical needs, accelerates its expansion in Oncology with its first-in-class four-in-one Bacterial Cell and Gene Therapy AUP-55. The company’s first abstract, Effect of multi-targeting bacterial gene therapy on tumor regression and survival in mouse models of ovarian and intraperitoneal cancer, has […]

Aurealis Therapeutics is attending the Swiss Biotech Day 2023

Juha Yrjänheikki (CEO) and Laurent Décory (COO) will be attending the Swiss Biotech Day 2023 which will take place from 24-25 April in Basel, Switzerland. This will be a fantastic opportunity to meet investors and discuss potential partnerships with pharma companies. The Swiss Biotech Day is one of the leading biotechnology conferences in Europe offering […]

Aurealis Therapeutics novel chronic wound treatment to be presented at the 4th Experts Meeting on Microbiome & Skin Health and Disease 2020

Haritha Samaranayake, MD, PhD, Medical Director of Aurealis Therapeutics will give a talk about development of AUP16, the company´s lead product for non-healing wounds such as diabetic foot ulcer. The presentation is titled “Development of a Live Biotherapeutic to treat diabetic foot ulcer“ and is scheduled for Tuesday, December 15th, 2020 at 14:30 CET. More […]

Aurealis Therapeutics to present at the European Wound Management Association (EWMA) Congress 2018

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CMO Dirk Weber will attend and discuss the company’s progress and clinical development plans for lead development product AUP-16 indicated for chronic wounds at the European Wound Management Association (EWMA) Congress in Krakow, Poland […]

Aurealis Therapeutics to attend the Swiss Biotech Day 2018

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki and CMO Dirk Weber will attend and discuss the company’s progress at the Swiss Biotech Day in Basel on May 3rd 2018. The Swiss Biotech Day has long become the standard annual get-together […]

Aurealis Therapeutics to present at the 11th Annual European Life Sciences CEO Forum & Exhibition

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki will attend and present the company’s progress at the 11th Annual European Life Sciences CEO Forum & Exhibition in Zurich on February 26-27th 2018. The presentation is scheduled for Monday, February […]

Aurealis Therapeutics to present at Swiss Nordic Bio 2018

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki will attend and present the company’s progress at the Swiss Nordic Bio 2018 partnering and investor event in Zurich on February 8th 2018. The presentation is scheduled for: Time: Thursday, February 8th 2018 […]